The proposal follows the success that Liquidia has recently had with vaccines and pulmonary products, including significant partnerships with GlaxoSmithKline and nonprofit organization PATH.
Liquidia Technologies CEO Neal Fowler said, "Developing a structure that allows for the creation and financing of new companies is a great fit for the ophthalmology focused business and is a structure we will continue to consider with other assets and therapeutic areas as we go forward."
The major product of the new ophthalmology company is being developed to treat glaucoma and is expected to initiate clinical studies in 2014.
Liquidia said further details of the new facility will be released later in the second quarter of 2013.
